Skip to content

Study · In vitro (cells) · 2013

2 results

Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.

van der Pas R, Feelders RA, Gatto F, de Bruin C, Pereira AM, van Koetsveld PM, Sprij-Mooij DM, Waaijers AM, Dogan F, Schulz S, Kros JM, Lamberts SW, Hofland LJ

The Journal of clinical endocrinology and metabolism30 Sept 2013Cited by 43 (Europe PMC)

PMID24081741 (opens in a new tab)DOI10.1210/jc.2013-1987 (opens in a new tab)PepBankPUB-24081741
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In normocortisolemic patients' adenoma cultures, 5 out of 6 responded to pasireotide, with ACTH secretion inhibition of -47.0% ± 4.2% among responders.

    In plain wordsIn cultured human adenoma cells, five of six cultures responded to pasireotide with reduced ACTH secretion.

    Peptide
    Pasireotide
    Outcome
    Not applicableACTH secretion responders
    Study

    humann = 6

    cultured human corticotroph adenoma cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In responders, octreotide (n = 2 out of 4; -30.5% ± 10.4%) was less potent than pasireotide (n = 5 out of 6; -47.0% ± 4.2%) and cabergoline (n = 3 out of 4; -41.9% ± 3.1%) with respect to inhibition of ACTH secretion by adenomas from group 2.
    2 context sentences
    Summary · context
    Corticotroph adenoma tissue was examined from patients from group 1 (n = 22; elevated preoperative urinary free cortisol) and group 2 (n = 11; mean duration of preoperative normocortisolism 10 weeks).
    Summary · context
    We evaluated receptor mRNA and protein expression levels and effects of octreotide, pasireotide, and cabergoline on ACTH secretion by cultured human corticotroph adenoma cells.
  2. 02LabIn vitro (cells)Activity measurement

    In normocortisolemic patients' adenoma cultures, pasireotide inhibited ACTH secretion more potently than octreotide, with responder inhibition of -47.0% ± 4.2% versus -30.5% ± 10.4%.

    In plain wordsIn cultured human adenoma cells, pasireotide inhibited ACTH secretion more potently than octreotide.

    Peptide
    Pasireotide
    Outcome
    DecreaseACTH secretion versus octreotide
    Study

    humann: not reported in source

    cultured human corticotroph adenoma cells
    Comparator
    octreotide
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In responders, octreotide (n = 2 out of 4; -30.5% ± 10.4%) was less potent than pasireotide (n = 5 out of 6; -47.0% ± 4.2%) and cabergoline (n = 3 out of 4; -41.9% ± 3.1%) with respect to inhibition of ACTH secretion by adenomas from group 2.
    2 context sentences
    Summary · context
    Corticotroph adenoma tissue was examined from patients from group 1 (n = 22; elevated preoperative urinary free cortisol) and group 2 (n = 11; mean duration of preoperative normocortisolism 10 weeks).
    Summary · context
    We evaluated receptor mRNA and protein expression levels and effects of octreotide, pasireotide, and cabergoline on ACTH secretion by cultured human corticotroph adenoma cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.